GE HealthCare Technologies Inc. 2022 Form 10-K Summary
Business context and reporting period
This annual report covers the fiscal year ended December 31, 2022. The filing presents combined carve-out financial statements for GE HealthCare’s former healthcare business within General Electric, rather than results of a fully independent company. GE HealthCare completed its spin-off from GE on January 3, 2023, and began regular-way Nasdaq trading under “GEHC” on January 4, 2023.
The company operates four segments: Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). It serves customers in more than 160 countries and has approximately 50,000 employees.
Financial performance and key metrics
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Total revenue | $18,341 million | $17,585 million | 4% reported; 7% organic |
| Gross profit | $7,179 million | $7,174 million | Flat |
| Operating income | $2,522 million | $2,795 million | Down 10% |
| Operating margin | 13.8% | 15.9% | Down 210 basis points |
| Net income attributable to GE HealthCare | $1,916 million | $2,247 million | Down 15% |
| Net income margin | 10.4% | 12.8% | Down 240 basis points |
| Adjusted EBIT | $2,861 million | $3,172 million | Down 10% |
| Adjusted EBIT margin | 15.6% | 18.0% | Down 240 basis points |
| Adjusted net income | $2,103 million | $2,347 million | Down 10% |
| Basic and diluted EPS from continuing operations | $4.18 | $4.91 | Down $0.73 |
| Cash flow from operating activities | $2,134 million | $1,607 million | Up 33% |
| Free cash flow | $1,828 million | $2,827 million | Down 35% |
Revenue growth was led by Imaging, which increased 6% reported and 10% organically, and Ultrasound, which increased 8% reported and 6% organically. PCS revenue was essentially flat reported but grew 3% organically. PDx revenue declined 3% reported but increased 2% organically.
Product revenue increased 8% to $12,044 million, while service revenue declined 2% to $6,297 million, primarily because of unfavorable foreign-currency effects. Gross profit was broadly unchanged because cost inflation offset revenue growth. Cost inflation in materials, logistics, labor, and other inputs, together with higher research and development and commercial investments, reduced operating profitability.
Research and development expense increased $210 million to $1,026 million. Selling, general, and administrative expense increased $68 million to $3,631 million. Restructuring costs were $146 million, and the company expects approximately $82 million of additional restructuring costs, primarily in 2023.
Cash flow, balance sheet, debt, and liquidity
- Operating cash flow increased to $2,134 million, supported by lower effects from discontinued factoring programs and higher accounts payable, partly offset by increased receivables, inventory investment, lower earnings, and higher cash taxes.
- Free cash flow declined to $1,828 million, primarily due to working-capital investment, higher cash taxes following mandatory capitalization of certain research and development costs under the Tax Cuts and Jobs Act, and lower net income.
- Capital expenditures were $310 million, compared with $248 million in 2021.
- Cash, cash equivalents, and restricted cash were $1,445 million on the balance sheet at December 31, 2022; cash reported in the cash-flow statement was $1,451 million.
- Total debt increased sharply to $8,249 million from $37 million. The increase resulted primarily from $8,250 million of senior unsecured notes issued in November 2022, with coupon rates ranging from 5.550% to 6.377% and maturities from 2024 through 2052.
- On January 3, 2023, the company drew $2,000 million under its term loan facility, bringing total principal borrowings to approximately $10,250 million. It began independent operations with approximately $1,800 million of cash, cash equivalents, and restricted cash.
- Available credit facilities include a $2,500 million five-year revolver, a $1,000 million 364-day revolver, and a $2,000 million three-year term loan. The facilities include customary covenants and a maximum consolidated net leverage ratio beginning with the quarter ending June 30, 2023.
- Management states that cash on hand, operating cash flow, and other liquidity sources should be sufficient to meet current and planned needs for at least the next 12 months.
Material changes versus the prior comparable period
- Revenue increased, but operating income and net income declined because inflation and increased strategic investment more than offset sales growth.
- Foreign currency translation was a significant headwind; organic revenue growth was 7% compared with 4% reported growth.
- China-region revenue declined 6%, primarily due to COVID-19 disruptions and foreign-currency effects. Revenue from Russia and Ukraine increased to $395 million from $356 million, although the company characterized those markets as a small portion of its business.
- PDx Segment EBIT decreased 25% to $520 million, reflecting China-related impacts and cost inflation. Imaging Segment EBIT decreased 11% to $1,100 million. Ultrasound Segment EBIT increased 3% to $908 million, while PCS Segment EBIT declined 4% to $341 million.
- Remaining performance obligations declined 2% to $14,343 million, driven mainly by the timing of U.S. multi-year service contract renewals. Product-related obligations were $4,992 million and service-related obligations were $9,351 million.
- Inventory increased to $2,155 million from $1,946 million, reflecting inventory build to meet expected 2023 demand and supply-chain constraints.
- The company acquired BK Medical in late 2021; the acquisition contributed to 2022 Ultrasound revenue. No significant acquisition was completed in 2022.
Outlook, management commentary, risks, and unusual items
Management expects long-term demand to benefit from precision care, healthcare digitization, demographic trends, emerging-market access, alternative sites of care, artificial intelligence, and clinical workflow automation. The company plans to increase investment in innovation, digital solutions, AI, software, and integrated care pathways while pursuing disciplined acquisitions and debt reduction.
The filing does not provide a clear quantitative 2023 revenue, earnings, margin, or cash-flow guidance range. Management expects increased stand-alone public-company costs, higher compensation and stock-based compensation expense, and separation-related dis-synergies as GE-provided services are replaced with internal or third-party capabilities.
- Spin-off and carve-out comparability: Historical combined results include GE cost allocations, centralized cash management, and GE-sponsored benefit arrangements. Future stand-alone costs and financing expenses may differ materially.
- Leverage and interest rates: The company assumed substantial debt at separation. Approximately 20% of total debt obligations consists of the variable-rate term loan, creating direct earnings and cash-flow sensitivity to interest rates.
- Pensions and benefits: GE transferred postretirement benefit obligations with a net liability of approximately $4,045 million, excluding additional company-sponsored plan liabilities. Expected 2023 benefit payments include approximately $141 million for the supplementary pension plan and $146 million for retiree health benefits.
- Supply chain and inflation: The company remains exposed to shortages, price volatility, logistics disruption, and availability of helium, iodine, rare earth minerals, and other components.
- Regulatory and product risks: Medical devices, pharmaceuticals, diagnostic agents, software, AI, data privacy, reimbursement, anti-corruption, and cybersecurity are subject to extensive and changing regulation.
- Tax matters: The spin-off is intended to be tax-free for U.S. federal purposes, but the company may have indemnification obligations to GE if the transaction fails to qualify or if specified restrictions are breached.
- Legal and environmental matters: The company disclosed litigation involving contracts with the Iraqi Ministry of Health and a pending approximately $0.6 million environmental fine related to a 2019 hazardous-waste incident at its Israel site. The filing states that a meaningful estimate of potential loss for certain legal matters is not currently available.
- Internal controls: Disclosure controls were deemed effective as of December 31, 2022. The filing does not include management’s assessment or an auditor attestation regarding internal control over financial reporting because of the SEC transition period for newly public companies.
Most important facts for investors to verify
- Reconcile post-spin-off stand-alone revenue, margins, cash flow, interest expense, taxes, and corporate costs with the historical carve-out figures.
- Monitor debt repayment capacity, net leverage, covenant compliance, refinancing needs, and the effect of variable-rate borrowings.
- Assess whether inflation, supply-chain constraints, foreign exchange, and China-related weakness continue to pressure margins and demand.
- Review the transferred pension and retiree-benefit obligations, expected funding requirements, and sensitivity to interest rates and asset returns.
- Track restructuring charges, separation costs, transition-service costs, and other expenses that may reduce 2023 cash flow.
- Evaluate the effect of GE’s retained ownership of up to 19.9% and potential future sales of GE HealthCare shares on stock-price volatility.
- Review the Tax Matters Agreement, indemnification provisions, and restrictions on acquisitions, asset sales, and equity issuance during the post-spin-off period.
- Confirm the status and potential exposure from disclosed litigation, regulatory matters, product warranties, guarantees, cybersecurity incidents, and environmental obligations.